基于早期CAR-T扩增的复发难治性LBCL动态风险分层
该回顾性分析纳入176例接受阿基仑赛治疗的复发难治性大B细胞淋巴瘤患者,用流式细胞术检测回输后第7、14、28天CAR-T细胞扩增,其中111例实时报告临床。第7天扩增≥48 cells/μL与PFS改善独立相关,且与CRS严重度和ICANS发生率升高相关。将CAR-T定量监测纳入临床可能动态优化风险分层。
要点
- 第7天CAR-T扩增≥48 cells/μL与PFS改善独立相关(HR 0.43)。
- 第7天扩增越高,CRS严重度和ICANS发生率越高。
- 糖皮质激素暴露增加反映毒性负担,但未与PFS不良相关。
核心结论
- 将CAR-T定量监测纳入临床实践可能动态优化回输后风险分层并指导个体化管理。
研究设计与样本
- 回顾性分析前瞻性收集的176例接受阿基仑赛治疗的复发难治性大B细胞淋巴瘤患者队列。
- 用流式细胞术检测回输后第7、14、28天CAR-T细胞扩增,111例实时报告临床。
主要发现
- 第7天扩增≥48 cells/μL与PFS改善独立相关(HR 0.43;95%CI 0.22-0.83;p=0.01)。
- 第7天扩增越高与CRS严重度增加和ICANS发生率升高相关。
- 糖皮质激素暴露增加反映毒性负担,但未与PFS不良相关。
关键数值与推荐
- 第7天CAR-T扩增≥48 cells/μL为独立关联PFS改善的阈值。
临床怎么用
- 可依据第7天CAR-T扩增水平动态细化回输后风险分层。
- 高扩增患者需关注CRS和ICANS毒性管理。
- 扩增水平可指导后续疾病进展监测频率的个体化安排。
局限性
- 回顾性分析设计。
- 仅111例实现CAR-T扩增实时报告临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T-cell expansion post-infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel). CAR T-cell expansion was measured by flow cytometry at days 7, 14 and 28 following infusion with real-time reporting to the clinical service in 111 patients. We examined the association between CAR T-cell expansion, efficacy (progression-free survival [PFS]), toxicity (cytokine release syndrome [CRS] and immune effector cell-associated neurotoxicity syndrome [ICANS]) and toxicity management, accounting for baseline risk factors. A multivariable model combining day 7 expansion with pre-lymphodepletion lactate dehydrogenase (LDH) and bridging response demonstrated that robust day 7 expansion (≥48 cells/μL) was independently associated with improved PFS (hazard ratio [HR], 0.43; 95% confidence interval [CI] 0.22-0.83; p = 0.01). Higher day 7 expansion was associated with increased CRS severity and ICANS incidence. Higher corticosteroid exposure reflected this toxicity burden but was not associated with inferior PFS. Thus, incorporating quantitative CAR-T enumeration into clinical practice may dynamically refine risk stratification post-infusion and guide individualised management, such as the frequency of monitoring for progressive disease in the era of effective subsequent therapies.
引用
- Panozzo B, Robinson S, Minson AG, et al. Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel. Br J Haematol. 2026. PMID: 42704001. doi:10.1111/bjh.70825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。